Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

The Inflammasome in Atherosclerosis and Type 2 Diabetes

(2011) S. L. Masters et al.   Science Translational Medicine

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

(2011) Jasmin B Kuemmerle-Deschner et al.   ARTHRITIS RESEARCH & THERAPY

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study

(2011) Naomi Schlesinger et al.   ARTHRITIS RESEARCH & THERAPY

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1β and suppressor of cytokine signalling-1 in mouse pancreatic beta cells

(2010) Panagiotis D. Venieratos et al.   CELLULAR SIGNALLING

Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome

(2010) Ioannis Mitroulis et al.   European Journal of Internal Medicine

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

(2010) Seth L Masters et al.   NATURE IMMUNOLOGY

Blockade of interleukin 1 in type 1 diabetes mellitus

(2010) Thomas Mandrup-Poulsen et al.   Nature Reviews Endocrinology

Free Fatty Acids Induce a Proinflammatory Response in Islets via the Abundantly Expressed Interleukin-1 Receptor I

(2009) Marianne Böni-Schnetzler et al.   ENDOCRINOLOGY

In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes

(2009) Helen J. Lachmann et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

(2009) Helen J. Lachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

(2009) J. A. Ehses et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity

(2008) O. Osborn et al.   CYTOKINE

Abnormalities in insulin secretion in type 2 diabetes mellitus

(2008) P.-J. Guillausseau et al.   DIABETES & METABOLISM

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Increased Interleukin (IL)-1β Messenger Ribonucleic Acid Expression in β-Cells of Individuals with Type 2 Diabetes and Regulation of IL-1β in Human Islets by Glucose and Autostimulation

(2008) Marianne Böni-Schnetzler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

(2008) Rieke Alten et al.   ARTHRITIS RESEARCH & THERAPY